Clinical Trial Update: Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate) [Phase 2]

View source ↗

Summary

A Phase 2 study of NX-1207 for Benign prostatic hyperplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• NX-1207

Snippet

Sponsor: Nymox Corporation | Conditions: Benign Prostatic Hyperplasia (BPH), Enlarged Prostate | Phase 2 | Status: COMPLETED